FDA gives Inamed another shot at market with silicone implants
This article was originally published in Clinica
Executive Summary
Inamed will get another chance to freely market its silicone-gel breast implants in the US. The FDA has notified the company that its supplemental submission on an earlier premarket approval application will be reviewed at a meeting of the agency's general and plastic surgery devices advisory panel, tentatively scheduled for April 2005.